Viatris Inc (VTRS) Sec Form 10K
Viatris Inc (NASDAQ: VTRS) Sec Form 10K
Viatris Inc (VTRS) Sec Form 8K
Viatris Inc (NASDAQ: VTRS) Sec Form 8K
Viatris Inc (VTRS) Dividend Update
Viatris Inc (NASDAQ: VTRS) Q1 2026 Dividend Update
Viatris Inc (VTRS) Q4 2025 Earnings Results
Viatris Inc (NASDAQ: VTRS) Q4 2025 Earnings Release
Viatris Inc (VTRS) Q4 2025 Earnings Call
Viatris Inc (NASDAQ: VTRS) Q4 2025 Earnings Conference
Viatris Inc (VTRS) FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
Viatris Inc (NASDAQ: VTRS) FY 2026 Other Release
Viatris Inc (VTRS) Q1 2021 Earnings Call Transcript
Viatris Inc (NASDAQ: VTRS) Q1 2021 Earnings Call dated May. 10, 2021 Corporate Participants: Melissa Trombetta — Head of Global Investor Relations Michael Goettler —…
Viatris Inc (VTRS) Q2 2025 Earnings Call Transcript
Viatris Inc (NASDAQ: VTRS) Q2 2025 Earnings Call dated Aug. 07, 2025 Corporate Participants: Bill Szablewski — Investor Relations Scott Smith — Chief Executive Officer,…
Viatris Inc (VTRS) Q3 2025 Earnings Call Transcript
Viatris Inc (NASDAQ: VTRS) Q3 2025 Earnings Call dated Nov. 06, 2025 Corporate Participants: Bill Szablewski — Investor Relations Scott A. Smith — Chief Executive…
Market News
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance
Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook for fiscal 2025.…